1 completed, 1 recruiting. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Recruiting 1 |
| Phase 2 | 1 | Completed 1 |
Follow Active Non-segmental Vitiligo: new trials by email Literature Review of Active Non-segmental Vitiligo trials Research Report on Active Non-segmental Vitiligo
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate the Safety, Tolerability and How IBI3013 is Taken up and Processed by the Body in Healthy Volunteers After Single-dose Administration, and in Non-segmental Vitiligo Patients and Alopecia Areata Patients After Multiple-dose Administration placebo, Baricitinib tablets, IBI3013 - Healthy, Active Non-segmental Vitiligo | Phase 1 | Recruiting | Innovent Biologics (Suzhou) Co. Ltd. | 160 | 2026-04-18 | 2026-04-28 |
| A Phase 2b Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Active Non-segmental Vitiligo Subjects PF-06651600, placebo, PF06700841 - Active Non-segmental Vitiligo | Phase 2 | Completed | Pfizer | 366 | 2018-11-26 | 2022-03-25 |
Alopecia Areata (1)
Alopecia (1) · Hair Diseases (1) · Hypotrichosis (1) · Skin Diseases (1) · Skin and Connective Tissue Diseases (1)
PF-06651600 (1) · PF-06700841 (1) · baricitinib (1)
Innovent Biologics (Suzhou) Co. Ltd. (1) · Pfizer (1)
Australia (1) · Belgium (1) · Canada (1) · China (1) · Germany (1) · Italy (1) · Japan (1) · South Korea (1) · Spain (1) · Taiwan (1) · United States (1)
PMID 36370907, PMID 37777018, PMID 37917289, PMID 39023568, PMID 42081176
2018 (1)